Corporate Members

Diamond Elite





Latest News

Radon Education

Radon, is the number one leading cause of lung cancer among non-smokers in the U.S. Radon is a colorless, odorless, and tasteless gas that you would have no way of knowing you were being exposed to.

Director of Nursing Diane Cope Authors Study on Pain Management Considerations in Older Cancer Patients

Fort Myers, FLA., September 5, 2019 — Florida Cancer Specialists & Research Institute (FCS) Director of Nursing, Diane G. Cope, PhD, APRN, BC, AOCNP, is the author of a study that focuses on the complex considerations for managing pain in older cancer patients.  Entitled “Cancer Pain Management Considerations in Older Adults,” the article was published in May 2019 in...

CMS coverage changes regarding CAR T Therapies

Recently, the Centers for Medicare and Medicaid Services (CMS) posted two announcements which impacts payment and coverage  for Chimeric Antigen Receptor T-Cell (CAR T) Therapies.  This email will provide a brief summary of the Fiscal Year (FY) 2020 Inpatient Prospective Payment System (IPPS) Final Rule, and the National Coverage Determination (NCD) for CAR T cell therapy...


Approval of a new product for myelofibrosis

Celgene is pleased to inform you of the US Food and Drug Administration’s recent approval of INREBIC® (fedratinib) capsules, a product from Celgene indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). Attached please find an announcement of this recent approval. http://cloud.info-celgene.com/inrebicpro INDICATION...

Announcing a New Genentech Therapy for ROS1+ mNSCLC and NTRK+ Solid Tumors

Dear Healthcare Professional:  Genentech is excited to share the news of a new FDA approval. ROZLYTREK™ (entrectinib) is now FDA approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. ROZLYTREK is also FDA approved for the treatment of adult and pediatric patients 12 years of age...

Who’s Online

There are no users currently online